Swen Seeland

Allschwil, BL 4123, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

ADME investigations of novel therapeutic modalities: challenges and opportunities 2025.

ADME investigations of novel therapeutic modalities: challenges and opportunities 2025.

Journal: Expert opinion on drug metabolism & toxicology
Published: March 23, 2026

Discovery and In-Vivo Characterization of Kv7 Channel Openers through a Phenotypic Approach.

Discovery and In-Vivo Characterization of Kv7 Channel Openers through a Phenotypic Approach.

Journal: Journal of medicinal chemistry
Published: August 12, 2025

The orexin 1-selective receptor antagonist nivasorexant is a time-dependent inhibitor of CYP2C19 and CYP3A4.

The orexin 1-selective receptor antagonist nivasorexant is a time-dependent inhibitor of CYP2C19 and CYP3A4.

Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: May 31, 2025

IDOR-1104-0086, a novel Kv7 channel activator with antiseizure effects in rodents.

IDOR-1104-0086, a novel Kv7 channel activator with antiseizure effects in rodents.

Journal: Neuropharmacology
Published: April 26, 2025

Discovery of CCR8 Antagonist IDOR-1136-5177 for the Treatment of Cancer.

Discovery of CCR8 Antagonist IDOR-1136-5177 for the Treatment of Cancer.

Journal: ChemMedChem
Published: December 02, 2024

Reversible oxidation/reduction steps in the metabolic degradation of the glycerol side chain of the S1P1 modulator ponesimod.

Reversible oxidation/reduction steps in the metabolic degradation of the glycerol side chain of the S1P1 modulator ponesimod.

Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: February 24, 2024

The metabolism of the orexin-1 selective receptor antagonist nivasorexant.

The metabolism of the orexin-1 selective receptor antagonist nivasorexant.

Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: February 15, 2024

The metabolism of the dual orexin receptor antagonist daridorexant.

The metabolism of the dual orexin receptor antagonist daridorexant.

Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: February 22, 2023

CYP3A4 Catalyzes the Rearrangement of the Dual Orexin Receptor Antagonist Daridorexant to 4-Hydroxypiperidinol Metabolites.

CYP3A4 Catalyzes the Rearrangement of the Dual Orexin Receptor Antagonist Daridorexant to 4-Hydroxypiperidinol Metabolites.

Journal: ChemMedChem
Published: January 20, 2023

Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data.

Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data.

Journal: Frontiers in pharmacology
Published: November 09, 2021

The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross-species comparison of its cytochrome P450 induction pattern.

The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross-species comparison of its cytochrome P450 induction pattern.

Journal: Pharmacology research & perspectives
Published: May 06, 2020

Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.

Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.

Journal: Journal of medicinal chemistry
Published: December 06, 2019
Showing 1-12 of 18

Last Updated: 09/26/2026